This article is more than 5 years old. Information may no longer be current.

Bromfenac indications expanded to include treatment of postop pain

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

IRVINE, Calif. – The nonsteroidal anti-inflammatory drug bromfenac has received U.S. regulators’ approval for a new indication, according to Ista Pharmaceuticals.

The Food and Drug Administration approved a supplemental new drug application to expand the indications for Xibrom (bromfenac 0.09%, Ista) to include pain treatment following cataract surgery, Ista announced in a press release.

Clinical trials found that 75% of cataract patients who experienced postoperative pain after cataract surgery were pain-free within 2 days of being treated with Xibrom, and 98% were pain-free within 6 days, according to the Ista press release.

“We are excited to receive this additional approval from the FDA, which we believe will expand the use of our product and greatly,” said Vicente Anido Jr., PhD, president and chief executive officer of Ista, in the press release.

Xibrom was approved in 2005 for treating postcataract inflammation. The topical NSAID was introduced to the U.S. market in the second quarter of 2005.